VivoSeq
53

Pipeline Programs

12

Active Trials

18

Companies Involved

Abscess is a moderately active landscape with 53 programs across 18 companies. The most active players are Novartis, Paratek Pharmaceuticals Inc, Daiichi Sankyo. 10 therapies are approved with 14 more in late-stage development.

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

27/100

Mech. Concentration

29/100

Completion Rate

72/100

Attrition Rate

18/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

98%

Small molecule

58 of 59 classified programs — the dominant modality here.

2%ALL OTHERSProtein / enzyme12%

Small molecule leads; the ring shows all 59 classified programs, each share of the total. Modality classified for 100% of 65 pipeline programs.

Trial Status

45

clinical trials

Completed21 · 47%
Recruiting5 · 11%
Terminated5 · 11%
Unknown status4 · 9%
Not yet recruiting4 · 9%
Enrolling by invitation3 · 7%
Other3 · 7%

Trial Activity

45 trials

Partial Oral Antibiotic Treatment for Bacterial Brain Abscess
Recruiting··Phase 4·NCT04140903·400 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)